| Literature DB >> 34905157 |
Jessica Barochiner1,2, Marcos J Marín3, Jorge J Janson3, Patricia R Conti3, Rocío Martínez3,4, Gabriel Micali3, Isabel E Conte3, Fernando Plazzotta5.
Abstract
INTRODUCTION: Cardiovascular risk seems not to be greater in patients with white coat uncontrolled hypertension (WUCH) than in patients with sustained blood pressure (BP) control. Therefore, its detection is important to avoid overtreatment. The COVID-19 pandemic determined a massive migration of hypertension consultations from the face-to-face modality to teleconsultations, and it is unknown whether WUCH exists in this context. AIM: We aimed to evaluate the prevalence of WUCH through home BP monitoring (HBPM) in treated hypertensive patients evaluated by teleconsultation.Entities:
Keywords: High blood pressure; Home blood pressure monitoring; Masked uncontrolled hypertension; Teleconsultation; White uncontrolled hypertension
Mesh:
Substances:
Year: 2021 PMID: 34905157 PMCID: PMC8669402 DOI: 10.1007/s40292-021-00498-y
Source DB: PubMed Journal: High Blood Press Cardiovasc Prev ISSN: 1120-9879
Baseline characteristics of the study population
| n | 341 |
| Male sex (%) | 45.2 |
| Age, years (SD) | 62.3 (13.9) |
| Smoking habits | |
| Current smoker (%) | 5.6 |
| Former smoker (%) | 26.4 |
| Diabetes (%) | 12.6 |
| Dyslipidemia (%) | 62.2 |
| History of ischemic heart disease (%) | 3.8 |
| History of cerebrovascular disease (%) | 4.7 |
| BMI, kg/m2 (SD) | 28.9 (4.9) |
| Fasting plasma glucose, mg/dL (IQR) | 100 (91–108) |
| Creatinine, mg/dL (IQR) | 0.92 (0.76–1.1) |
| Total cholesterol, mg/dL (SD) | 185.4 (38.4) |
BMI body mass index, IQR interquartile range, SD standard deviation
Characteristics of antihypertensive treatment
| Number of antihypertensive drugs (SD) | 2.1 (1) |
|---|---|
| Diuretics (%) | 26.1 |
| Beta-blockers (%) | 36.1 |
| ACEI (%) | 31.7 |
| ARB (%) | 52.8 |
| CCB (%) | 50.1 |
| Aldosterone antagonists (%) | 5.9 |
| Alpha-blockers (%) | 2.3 |
| Other (%) | 0.9 |
ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, CCB calcium channel blockers, SD standard deviation
Blood pressure profiles in teleconsultation and during home blood pressure monitoring
| BP in teleconsultation | |
|---|---|
| SBP 1, mm Hg (SD) | 142.8 (14.2) |
| DBP 1, mm Hg (SD) | 83.8 (10.2) |
| HR 1, bpm (SD) | 73.4 (11.9) |
| SBP 2, mm Hg (SD) | 137.4 (14.3) |
| DBP 2, mm Hg (SD) | 82.6 (9.9) |
| HR 2, bpm (SD) | 71.9 (11.8) |
| Mean SBP, mmHg (SD) | 140.1 (13.6) |
| Mean DBP, mmHg (SD) | 83.2 (9.6) |
| Mean HR, bpm (SD) | 72.6 (11.7) |
BP blood pressure, BPM beats per minute, DBP diastolic blood pressure, HBPM home blood pressure monitoring, HR heart rate, SBP systolic blood pressure, SD standard deviation
Comparison of patients with sustained controlled hypertension, white coat uncontrolled hypertension, masked uncontrolled hypertension and sustained uncontrolled hypertension
| Characteristic | SCH (n = 107) | WUCH (n = 113) | MUCH (n = 27) | SUCH (n = 94) | p value |
|---|---|---|---|---|---|
| Male sex (%) | 40.2 | 44.3 | 51.9 | 50 | 0.48 |
| Age, years (SD) | 59.6 (13.6) | 61 (12.8) | 66.7 (12.6) | 65.8 (14.8) | 0.003 |
| Smoking habits | |||||
| Current smoker (%) | 6.5 | 6.3 | 7.4 | 6.4 | 0.93 |
| Former smoker (%) | 27.1 | 24.8 | 29.6 | 26.6 | 0.93 |
| Diabetes (%) | 13.1 | 14.2 | 11.1 | 17 | 0.36 |
| Dyslipidemia (%) | 63.6 | 58.4 | 66.7 | 63.8 | 0.78 |
| History of ischemic heart disease (%) | 2.8 | 2.7 | 3.7 | 6.4 | 0.49 |
| History of cerebrovascular disease (%) | 7.5 | 3.5 | 0 | 4.3 | 0.31 |
| BMI, kg/m2 (SD) | 29.3 (5.5) | 28.5 (4.9) | 29.1 (3.2) | 29.1 (4.6) | 0.68 |
| Fasting plasma glucose, mg/dL (SD) | 101.5 (17.5) | 99.5 (12.3) | 107.9 (14) | 103.7 (18) | 0.07 |
| Creatinine, mg/dL (SD) | 0.9 (0.2) | 0.96 (0.4) | 1.02 (0.4) | 1 (0.3) | 0.13 |
| Total cholesterol, mg/dL (SD) | 185.6 (37.7) | 181.7 (37.1) | 185.6 (27.5) | 189.9 (43.3) | 0.06 |
| BP in teleconsultation | |||||
| Mean SBP, mmHg (SD) | 127 (8.6) | 147.8 (9.1) | 130.7 (7.6) | 148.5 (10.5) | < 0.001 |
| Mean DBP, mmHg (SD) | 78.8 (7) | 86.2 (9) | 75.8 (8.2) | 86.6 (10.2) | < 0.001 |
| Mean HR, bpm (SD) | 73.6 (13.2) | 72.9 (10.8) | 70.4 (8.3) | 71.7 (11.6) | 0.50 |
HBPM 7-day SBP, mmHg (SD) | 118.7 (7.8) | 124.5 (6.3) | 137.2 (7.6) | 139.1 (10.2) | < 0.001 |
| 7-day DBP, mmHg (SD) | 75.1 (5.7) | 76.1 (6.4) | 80.3 (7.2) | 81.8 (7.8) | < 0.001 |
| Mean HR, bpm (SD) | 70.9 (9.7) | 68 (8.1) | 69.7 (10.7) | 68.3 (9.4) | 0.10 |
| SBP discarding first day measurements, mmHg (SD) | 118.6 (7.9) | 124 (6.3) | 137.6 (7.9) | 139 (10.3) | < 0.001 |
DBP discarding first day measurements, mmHg (SD) | 75 (5.8) | 75.8 (6.4) | 80.1 (7) | 81.8 (7.8) | < 0.001 |
| Morning SBP, mmHg (SD) | 117.8 (8.9) | 122.4 (7.7) | 137.1 (9.6) | 137.7 (12.2) | < 0.001 |
| Morning DBP, mmHg (SD) | 74.9 (6.2) | 75.6 (6.7) | 80.3 (7.8) | 81.6 (8.3) | < 0.001 |
| Evening SBP, mmHg (SD) | 119.4 (8.6) | 125.5 (8) | 137.5 (9.9) | 140.1 (10.7) | < 0.001 |
| Evening DBP, mmHg (SD) | 75.2 (6.1) | 75.9 (7.1) | 79.6 (6.7) | 81.9 (8.3) | < 0.001 |
| Number of antihypertensive drugs (SD) | 1.9 (0.9) | 1.9 (1) | 2.4 (1) | 2.3 (1) | 0.004 |
| Diuretics (%) | 22.4 | 23.9 | 37 | 29.8 | 0.34 |
| Beta-blockers (%) | 34.6 | 35.4 | 40.7 | 37.2 | 0.93 |
| ACEI (%) | 29 | 38.1 | 22.2 | 29.8 | 0.29 |
| ARB (%) | 52.3 | 44.3 | 63 | 60.6 | 0.08 |
| CCB (%) | 46.7 | 38.9 | 66.7 | 62.8 | 0.002 |
| Aldosterone antagonists (%) | 5.6 | 6.2 | 7.4 | 5.3 | 0.98 |
| Alpha-blockers (%) | 0.9 | 3.5 | 3.7 | 2.1 | 0.6 |
| Other (%) | 0 | 0.9 | 3.7 | 1.1 | 0.33 |
ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, BMI body mass index, BP blood pressure, bpm beats per minute, CCB calcium channel blockers, DBP, diastolic blood pressure, HR heart rate, MUCH masked uncontrolled hypertension, SBP systolic blood pressure, SCH sustained controlled hypertension, SD standard deviation, SUCH sustained uncontrolled hypertension, WUCH white coat uncontrolled hypertension